[Comparison of colloidal bismuth subcitrate with ranitidine in healing and relapse of Campylobacter pylori-associated duodenal ulcers].
Eighty patients with Campylobacter pylori-associated duodenal ulcer disease were randomly allocated to receive colloidal bismuth subcitrate (CBS)tablet 120 mg four times a day or ranitidine 150 mg twice daily in a trial comparing the effects of these drugs in short-term healing and post-healing relapse rates of duodenal ulceration. At 8 weeks 88.1% (37/42) of those on CBS and 92.1% (35/38) of those on ranitidine had ulcers healed. The difference is not significant. After ulcer healing, the cumulative rates of relapse, as determined endoscopically, for symptomatic and asymptomatic ulcers were 19.4% (6/31) for CBS and 46.7% (14/30) for ranitidine at 6 months (P less than 0.05) and 41.9% (13/31) for CBS and 73.3% (22/30) for ranitidine at 12 months (P less than 0.05). As campylobacter pylori was cleared in 35 of the 42 patients (83.3%) in the CBS group, while only one of the 38 patients (2.63%) in the ranitidine group (P less than 0.005), it is possible that the clearance of Campylobacter pylori by CBS is instrumental to the reduction of the rate of reulceration.
Hu
F L
FL
Department of Gastroenterology, First Teaching Hospital, Beijing Medical University.
Jia
B Q
BQ
Gao
H Z
HZ
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D016481:Helicobacter Infections; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate